Effects of RAS in SZ

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorShu-Mei Wang

About this trial

The two main groups of medicated patients with schizophrenia (SZ) are those receiving second-generation antipsychotics and those receiving first-generation antipsychotics. The purpose of this research project is to target each patient group to examine effects of rhythmic auditory stimulation (RAS) on upper-limb movements in medicated SZ patients in a 6-month follow-up period.

The main questions of this project are:

1. Does RAS reduce severity of upper-limb bradykinesia (slow movements) and dyskinesia (repetitive and involuntary movements) after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving second-generation antipsychotics? and 2. Does RAS reduce severity of upper-limb bradykinesia and dyskinesia after intervention, at 3-month follow-up and 6-month follow-up in SZ patients receiving first-generation antipsychotics?

Researchers will compare upper-limb movement training with the aid of RAS to upper-limb movement training without the aid of RAS to see if RAS works to improve upper-limb movements in SZ patients. Participants will:

1. Undergo an interview and movement tests and fill out questionnaires before and after the movement training program and at 3-month follow-up and 6-month follow-up; and 2. Receive movement training for 40 minutes per session for a total of 21 sessions.

Eligibility criteria

Qualifiers

A diagnosis of schizophrenia or schizoaffective disorder

Between 18 to 60 years old

Keeping the same antipsychotics and the same dosage at least 4 weeks right before joining the study

A Edinburgh Handedness Inventory score of > 60

Disqualifiers

Substance abuse or drug abuse

Neurological diseases or medical conditions that affect upper-limb movements and hearing

Other psychiatric diagnoses in addition to a diagnosis of schizophrenia or schizoaffective disorder

Between 18 to 60 years old

Trial design

Treatments tested in this trial

  • RAS incorporated in upper-limb movement training
  • Upper-limb movement training

Treatment groups

140 Participants
are divided into 4 treatment groups

Sponsors and collaborators

Shu-Mei Wang

Lead sponsor

National Taipei University of Nursing and Health Sciences

Sponsor institution